Skip to main
ICLR

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 29%
Buy 36%
Hold 29%
Sell 7%
Strong Sell 0%

Bulls say

Icon is a well-established and globally recognized contract research organization with a diverse range of services and partnerships within the life sciences industry. Despite potential short-term challenges such as a decline in revenue and impacts from divestitures, the company is investing in technology and maintains a strong internal execution track record, positioning them for long-term growth and success. However, delays in clinical trials due to the ongoing pandemic may hinder their financial standing and reputation, highlighting the importance of the company's focus on growth and investor confidence.

Bears say

Icon is experiencing positive trends and increasing gross bookings, but challenges such as canceled bookings and pricing pressures remain. Their successful biotech investment strategy and partnerships with early-stage companies provide potential for growth, but potential risks such as accounting issues and delays in clinical trials could affect their rating and price target. Lack of disclosures on key performance indicators hinders a more positive outlook, but the company's focus on sustainability is a positive factor.

ICON (ICLR) has been analyzed by 14 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 36% recommend Buy, 29% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 14 analysts, ICON (ICLR) has a Buy consensus rating as of Jun 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $180.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $180.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.